Security readout for executives and security teams
Plain-English summary
CVE-2015-1617 is an authenticated cross-site scripting issue in the ePO extension for McAfee Data Loss Prevention Endpoint before 9.3.400. A logged-in remote user could inject web script or HTML through unspecified vectors. Business impact depends on who can access the ePO interface and what privileges their session has.
Executive priority
Treat this as a managed-product hygiene issue, not an emergency based on available evidence. Prioritize remediation if ePO is broadly reachable, used by many administrators, or protects sensitive DLP operations.
Technical view
The public record describes XSS in the McAfee DLPe ePO extension before 9.3.400. The vulnerable input path is not specified. No CVSS score, CWE, or detailed attack preconditions are provided beyond remote authenticated access. The practical risk is session-context script execution inside the management interface.
Likely exposure
Exposure is most likely where McAfee Data Loss Prevention Endpoint with the ePO extension is deployed below version 9.3.400 and reachable by authenticated users. Internet exposure is not established by the sources.
Exploitation context
The source bundle does not show CISA KEV listing or cited evidence of active exploitation. The issue requires authentication according to the CVE description, and exploit vectors are unspecified.
Researcher notes
Public details are sparse: the CVE states authenticated XSS with unspecified vectors, no CVSS, and no CWE. Avoid assuming stored versus reflected behavior, affected pages, or exploitability beyond script or HTML injection in authenticated ePO context.
Mitigation direction
- Confirm installed McAfee DLPe ePO extension versions.
- Upgrade affected deployments to 9.3.400 or later if vendor guidance confirms applicability.
- Review McAfee advisory SB10098 for official remediation details.
- Restrict ePO access to trusted administrative networks and users.
- Monitor ePO sessions for unexpected script behavior or account activity.
Validation and detection
- Inventory ePO extensions and record DLPe extension versions.
- Check whether any DLPe ePO extension is earlier than 9.3.400.
- Verify access controls limit ePO to authorized users only.
- Review vendor advisory SB10098 for product-specific confirmation.
- Document compensating controls if immediate upgrade is not possible.
Public sources used
Generated from the cited source records. This long-tail analysis has not been individually reviewed by a named human.
Conservative CVE-to-ATT&CK context
These mappings and lookup hints may be relevant to the vulnerability behavior, CWE, affected product, or exposure path. Glexia-inferred context is not an official MITRE, ATT&CK, CWE, or CVE Program mapping.
ATT&CK lookup starting points
Use these exact CWE pages and searches to review the Glexia ATT&CK library from this CVE's weakness and description context.
CVE-2015-1617 mapping review
Open the CVE-to-ATT&CK bridge for reviewed, inferred, or future official mappings tied to this CVE.
Open ATT&CK lookup- Severity
- Unknown
- CVSS
- Not scored
- Known Exploited
- No
- Published
CNA and ADP enrichment extracted from CVE v5
These fields come from the CVE record and ADP containers, not from Glexia's Take. They preserve time-varying source decisions such as CISA SSVC, KEV status, CVSS metrics, and provider references.
CVSS and timeline data
No CVSS vectors or timeline events were available in the normalized CVE source material.
Source materials
- CVE List V5 sourceCVE List V5
- https://kc.mcafee.com/corporate/index?page=content&id=SB10098CVE reference · x_refsource_CONFIRM
Products and packages named in the record
CWE details
CWE links open Glexia weakness intelligence pages with official CWE context, developer remediation guidance, and related CVE mappings.